Navigation Links
Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
Date:3/30/2011

STEWARTVILLE, Minn., March 30, 2011 /PRNewswire/ -- Rochester Medical Corporation (Nasdaq: ROCM) announced that the shareholders of Fornix BioSciences N.V. today approved the previously announced sale of Laprolan B.V. its Medical Supplies Division and wholly owned subsidiary to Rochester Medical Corporation.

Rochester Medical expects the transaction to close in the near term, and under the terms of the Share Purchase Agreement between Rochester Medical and Fornix, be deemed retroactive to January 1, 2011.  For more information regarding this transaction please refer to the Company's January 12, 2011 press release.

This press release contains "forward-looking statements" with the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements include, but are not limited to, statements about the expected completion of the acquisition of Laprolan.  Such statements are based on currently available information, operating plans and management's expectations about future events and trends.  Such statements inherently involve significant risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2010.  Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made.  The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Rochester Medical Corporation develops, manufactures, and markets latex-free disposable medical catheters and devices for urological and continence care applications.  The Company markets under its own Rochester Medical® brand and under existing private label arrangements.

For further information, please contact Anthony J. Conway, President and Chief Executive Officer or David A. Jonas, Chief Financial Officer of Rochester Medical Corporation at (507) 533-9600.  More information about Rochester Medical is available on its website at http://www.rocm.com.


'/>"/>
SOURCE Rochester Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split
2. Tongjitang Chinese Medicines Company Announces Extraordinary General Meeting of Shareholders
3. Caraco Announces Merger Agreement with Sun Pharma; Caraco Public Shareholders to Receive $5.25 Cash per Share
4. Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
5. Amarin Provides 2010 Year-End Review to Shareholders
6. BD Announces Webcast of Annual Meeting of Shareholders
7. Penwest Pharmaceuticals Shareholders Approve Merger With Subsidiary of Endo Pharmaceuticals
8. Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010
9. China Sky One Medical, Inc. Reports Outcome of Annual Meeting of Shareholders
10. Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock
11. United American Healthcare Corporation Announces Results of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... 19, 2017 Shire plc (LSE: ... U.S. Food and Drug Administration (FDA) has acknowledged receipt ... Application (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine ... once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is ... 20, 2017, the designated Prescription Drug User Fee Act ...
(Date:1/19/2017)... The global  pacemaker market  is expected to reach USD ... Inc. The heightening prevalence of cardiac conditions coupled with the availability of medical ... addition, technological enhancements in these devices are supporting the expansion of this vertical. ... ... Grand View Research Logo ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. ... Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology ... Dr. Li completed his internship in internal medicine at the Emory University and ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... now offering treatments for patients with sleep apnea and TMJ disorders. These conditions ... and physical health. Dr. Rassouli provides personalized care to reduce the risk of ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree ... planning services to communities throughout eastern Georgia, is embarking on a charity effort ... Heart disease kills more Americans every year than anything else, yet risk factors ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative messages ... Real Impact contest from Impact Teen Drivers and California Casualty. Entries from students ... , Educational grants totaling $15,000 will be awarded for the best peer-to-peer messages ...
(Date:1/19/2017)... ... , ... The 21st Century Cures Act’s Impact on Medical Devices:, What You ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do ... this year? , The passage of the act means devicemakers will be scrambling to ...
Breaking Medicine News(10 mins):